Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

NCT01760642 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: Midazolam
DRUG: Ketoconazole
DRUG: Rifampicin

Sponsor

Seoul National University Hospital